Missouri marijuana firms are on edge as the IRS finally reclassifies medical cannabis, promising tax relief that could reshape their finances. The move could slash effective tax rates from up to 80% to a fraction of that, but rules are still unclear.
Federal officials placed medical cannabis in Schedule III while recreational stays in Schedule I, creating a tax dilemma for businesses that hold comprehensive licenses covering both markets.
Section 280E bars cannabis firms from deducting ordinary expenses, resulting in effective tax rates that can reach 80% despite a standard corporate rate of 21%.
Missouri permits state‑level deductions for those expenses, but the federal restriction remains in place.
Andrew Mullins, executive director of the Missouri Cannabis Trade Association, said the industry anxiously awaits IRS guidance that will dictate allowable deductions.
The Treasury Department and IRS listed Section 280E guidance among their fiscal year 2027 priorities, a list that includes more than 100 other tasks.
Amy Moore, director of the Missouri Division of Cannabis Regulation, warned that the order creates a particular challenge for states where a single license covers both medical and adult‑use sales.
Drew Lammert, chair of the trade association’s government affairs committee and co‑founder of High Fidelity Brands, said companies may have to decide how to split expenses between medical and recreational operations while waiting for federal clarification. He noted his firm’s medical sales account for only 10% of revenue and said, “We are excited, but there’s also those questions of the unknowns, and what does that mean for the 90% of adult‑use sales out there.”
Separating the weed
Missouri issues comprehensive licenses that let businesses serve both medical patients and recreational customers, eliminating the need to separate plants during cultivation.
Because the same staff, facilities, and inventory serve both markets, companies must allocate costs to the medical portion to qualify for federal deductions.
Preparing for tax season without answers
The Treasury Department and IRS warned that the rescheduling order could produce significant positive tax consequences for medical marijuana businesses.
Kevin Jednachowski, chief value officer of Mindtrix Accounting, told The Independent that firms need concrete IRS guidance to file accurate returns, and the timeline remains uncertain. He warned that estimates can slip or be delayed, and the eventual guidance may be narrower than earlier statements.
Until the IRS clarifies the rules, cannabis companies must craft tax estimates for 2026, with the final estimated payment due December 15. Underpaying triggers penalties and interest, while overpaying ties up cash that may take months to be refunded.
Jednachowski said the gap between possible outcomes can affect payroll, vendor terms, and planned build‑outs, urging operators to know the size of the gap now. He recommends maintaining detailed records of costs tied to medical operations, documenting how shared expenses are divided. Such documentation lets businesses adjust calculations if new guidance emerges, ensuring they can justify which dollars belong to which part of the operation.
The story was first published by Missouri Independent.
Photo courtesy of Chris Wallis // Side Pocket Images.
Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
